UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 87 filers reported holding UROGEN PHARMA LTD in Q4 2019. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $3,974,000 | -86.0% | 222,776 | -73.8% | 0.97% | -78.4% |
| Q4 2019 | $28,347,000 | +35.6% | 849,478 | -3.2% | 4.49% | +47.2% |
| Q3 2019 | $20,902,000 | -42.6% | 877,120 | -13.5% | 3.05% | +14.4% |
| Q2 2019 | $36,446,000 | -0.0% | 1,014,078 | +2.8% | 2.67% | +16.4% |
| Q1 2019 | $36,455,000 | +83.4% | 986,878 | +113.8% | 2.29% | +72.0% |
| Q4 2018 | $19,880,000 | +26.8% | 461,678 | +39.1% | 1.33% | +83.7% |
| Q3 2018 | $15,676,000 | -5.1% | 331,900 | 0.0% | 0.72% | +31.1% |
| Q2 2018 | $16,515,000 | -11.8% | 331,900 | -11.9% | 0.55% | -13.5% |
| Q1 2018 | $18,724,000 | +25.8% | 376,823 | -5.8% | 0.64% | +29.9% |
| Q4 2017 | $14,880,000 | +15.1% | 399,900 | -2.5% | 0.49% | +34.1% |
| Q3 2017 | $12,923,000 | +68.2% | 410,000 | -3.6% | 0.37% | +51.0% |
| Q2 2017 | $7,681,000 | – | 425,300 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |